

## ACYCLOVIR OINT (CCHP2017)

---

### Products Affected

#### Step 2:

- *acyclovir 5 % topical ointment*

### Details

<b>Criteria</b>	Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir.
-----------------	---------------------------------------------------------------------------------------------------------------------------------------

## ALPHAGAN (CCHP2017)

---

### Products Affected

#### Step 2:

- ALPHAGAN P 0.1 % EYE DROPS
- COMBIGAN 0.2 %-0.5 % EYE DROPS
- SIMBRINZA 1 %-0.2 % EYE DROPS,SUSPENSION

### Details

---

Criteria
Step Therapy requires trial of brimonidine 0.15% or brimonidine 0.2%.

---

## ANTIDEPRESSANT\_NVT 2017

---

### Products Affected

#### Step 2:

- DESVENLAFAXINE ER 100 MG TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE ER 50 MG TABLET,EXTENDED RELEASE 24 HR
- DRIZALMA SPRINKLE 20 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 30 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 40 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 60 MG CAPSULE,DELAYED RELEASE
- *duloxetine 40 mg capsule, delayed release*
- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- FETZIMA 120 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE,EXTENDED RELEASE
- *fluvoxamine er 100 mg capsule, extended release 24 hr*
- *fluvoxamine er 150 mg capsule, extended release 24 hr*
- MARPLAN 10 MG TABLET
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET
- VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
- VIIBRYD 10 MG TABLET
- VIIBRYD 20 MG TABLET
- VIIBRYD 40 MG TABLET

### Details

<b>Criteria</b>	Step Therapy requires trial of one of the following generic SSRI's in previous 120 days: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, Paxil oral solution, or fluvoxamine. If request is for duloxetine, step not required for diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain.
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## ARICEPT 23\_NVT 2015

---

### Products Affected

**Step 2:**

- *donepezil 10 mg disintegrating tablet*
- *donepezil 5 mg disintegrating tablet*

### Details

---

<b>Criteria</b>	Step Therapy requires trial of regular donepezil 5 mg or 10mg oral tablets in previous 120 days.
-----------------	--------------------------------------------------------------------------------------------------

---

## **COPD**

---

### **Products Affected**

**Step 2:**

- INCRUSE ELLIPTA 62.5  
MCG/ACTUATION POWDER FOR  
INHALATION

### **Details**

---

<b>Criteria</b>	Step Therapy requires a trial of Spiriva or Spiriva Respimat in previous 120 days.
-----------------	------------------------------------------------------------------------------------

---

# 2021 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria  
*Updated 4/2021*

## DEXILANT\_2019

---

### Products Affected

#### Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE

### Details

---

Criteria
Step therapy requires trial of lansoprazole in the previous 120 days.

---

# 2021 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria  
*Updated 4/2021*

## DPP4

---

### Products Affected

#### Step 2:

- KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE
- ONGLYZA 2.5 MG TABLET
- ONGLYZA 5 MG TABLET

### Details

---

<b>Criteria</b>	Step Therapy requires trial of Januvia, Janumet, or Janumet XR in the past 120 days.
-----------------	--------------------------------------------------------------------------------------

---

## **DRY EYE OTC (CCHP 2018)**

---

### **Products Affected**

#### **Step 2:**

- RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE

### **Details**

---

<b>Criteria</b>	
	Step Therapy requires trial of OTC artificial tears.

---



## GLUCAGON

---

### Products Affected

#### Step 2:

- BAQSIMI 3 MG/ACTUATION NASAL SPRAY
- GLUCAGEN HYPOKIT 1 MG INJECTION
- GLUCAGON EMERGENCY KIT 1 MG SOLUTION FOR INJECTION

### Details

---

Criteria	
	Step Therapy requires a trial of Gvoke in the previous 120 days.

---

## OPHTHALMIC ANTI-INFECTIVES\_NVT 2015

---

### Products Affected

#### Step 2:

- BESIVANCE 0.6 % EYE DROPS,SUSPENSION
- *gatifloxacin 0.5 % eye drops*

### Details

<b>Criteria</b>	Step Therapy requires trial of one of the following ciprofloxacin, levofloxacin, or ofloxacinin previous 120 days.
-----------------	--------------------------------------------------------------------------------------------------------------------

## PANCREATIC ENZYMES\_NVT 2015

---

### Products Affected

#### Step 2:

- PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE

### Details

---

Criteria
Step Therapy requires trial of CREON in previous 120 days.

---

## POLYETHYLENE GLYCOL

---

### Products Affected

#### Step 2:

- LINZESS 145 MCG CAPSULE
- LINZESS 290 MCG CAPSULE
- LINZESS 72 MCG CAPSULE
- MOVANTIK 12.5 MG TABLET
- MOVANTIK 25 MG TABLET
- RELISTOR 12 MG/0.6 ML  
SUBCUTANEOUS SOLUTION
- RELISTOR 12 MG/0.6 ML  
SUBCUTANEOUS SYRINGE
- RELISTOR 8 MG/0.4 ML  
SUBCUTANEOUS SYRINGE

### Details

<b>Criteria</b>	Step Therapy requires trial of OTC polyethylene glycol in the past 120 days.
-----------------	------------------------------------------------------------------------------

## ST\_RIVASTIGMINE\_2019

---

### Products Affected

#### Step 2:

- *rivastigmine 13.3 mg/24 hour transdermal patch*
- *rivastigmine 9.5 mg/24 hour transdermal patch*
- *rivastigmine 4.6 mg/24 hour transdermal patch*

### Details

---

Criteria
Step Therapy requires trial of rivastigmine tablets in past 120 days.

---

## ST\_SMOKINGCESS\_2019

---

### Products Affected

#### Step 2:

- *bupropion hcl 150 mg tablet, 12 hr sustained-release(smoking deterrent)*

### Details

---

Criteria	Step therapy requires trial of nicotine patches in previous 120 days.
----------	-----------------------------------------------------------------------

---

## ULORIC\_NVT 2015

---

### Products Affected

#### Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*

### Details

---

Criteria	
	Step Therapy requires trial of allopurinol in previous 120 days.

---

## ZADITOR OTC (CCHP2017)

---

### Products Affected

**Step 2:**

- *olopatadine 0.1 % eye drops*

**Step 3:**

- *olopatadine 0.2 % eye drops*

### Details

---

<b>Criteria</b>	Step Therapy requires trial of OTC zaditor/ketotifen for olopatadine ophth soln. Trial of olopatadine 1 mg/ml ophth soln required for olopatadine 2 mg/ml.
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------

---



# 2021 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria  
Updated 4/2021

## INDEX

### A

acyclovir 5 % topical ointment.....1  
ALPHAGAN P 0.1 % EYE DROPS .....2

### B

BAQSIMI 3 MG/ACTUATION NASAL  
SPRAY .....9  
BESIVANCE 0.6 % EYE  
DROPS,SUSPENSION .....10  
bupropion hcl 150 mg tablet,12 hr sustained-  
release(smoking deterrent) .....14

### C

COMBIGAN 0.2 %-0.5 % EYE DROPS....2

### D

DESVENLAFAXINE ER 100 MG  
TABLET,EXTENDED RELEASE 24 HR  
.....3  
DESVENLAFAXINE ER 50 MG  
TABLET,EXTENDED RELEASE 24 HR  
.....3

DEXILANT 30 MG CAPSULE,  
DELAYED RELEASE.....6

DEXILANT 60 MG CAPSULE,  
DELAYED RELEASE.....6

donepezil 10 mg disintegrating tablet.....4  
donepezil 5 mg disintegrating tablet.....4

DRIZALMA SPRINKLE 20 MG  
CAPSULE,DELAYED RELEASE .....3

DRIZALMA SPRINKLE 30 MG  
CAPSULE,DELAYED RELEASE .....3

DRIZALMA SPRINKLE 40 MG  
CAPSULE,DELAYED RELEASE .....3

DRIZALMA SPRINKLE 60 MG  
CAPSULE,DELAYED RELEASE .....3

duloxetine 40 mg capsule,delayered release...3

### E

EMSAM 12 MG/24 HR TRANSDERMAL  
24 HOUR PATCH.....3

EMSAM 6 MG/24 HR TRANSDERMAL  
24 HOUR PATCH.....3

EMSAM 9 MG/24 HR TRANSDERMAL  
24 HOUR PATCH.....3

### F

febuxostat 40 mg tablet .....15  
febuxostat 80 mg tablet .....15  
FETZIMA 120 MG

CAPSULE,EXTENDED RELEASE .....3  
FETZIMA 20 MG (2)-40 MG (26)

CAPSULE,EXTENDED RELEASE,24  
HR,DOSE PACK .....3

FETZIMA 20 MG CAPSULE,EXTENDED  
RELEASE.....3

FETZIMA 40 MG CAPSULE,EXTENDED  
RELEASE.....3

FETZIMA 80 MG CAPSULE,EXTENDED  
RELEASE.....3

fluvoxamine er 100 mg capsule,extended  
release 24 hr.....3

fluvoxamine er 150 mg capsule,extended  
release 24 hr.....3

### G

gatifloxacin 0.5 % eye drops .....10  
GLUCAGEN HYPOKIT 1 MG

INJECTION.....9  
GLUCAGON EMERGENCY KIT 1 MG

SOLUTION FOR INJECTION .....9

### I

INCRUSE ELLIPTA 62.5  
MCG/ACTUATION POWDER FOR  
INHALATION .....5

### K

KOMBIGLYZE XR 2.5 MG-1,000 MG  
TABLET,EXTENDED RELEASE .....7

KOMBIGLYZE XR 5 MG-1,000 MG  
TABLET,EXTENDED RELEASE .....7

KOMBIGLYZE XR 5 MG-500 MG  
TABLET,EXTENDED RELEASE .....7

### L

LINZESS 145 MCG CAPSULE .....12  
LINZESS 290 MCG CAPSULE .....12

LINZESS 72 MCG CAPSULE .....12

### M

MARPLAN 10 MG TABLET .....3  
MOVANTIK 12.5 MG TABLET.....12

## 2021 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria

Updated 4/2021

MOVANTIK 25 MG TABLET.....12

### O

olopatadine 0.1 % eye drops.....16

olopatadine 0.2 % eye drops.....16

ONGLYZA 2.5 MG TABLET .....7

ONGLYZA 5 MG TABLET .....7

### P

PANCREAZE 10,500 UNIT-35,500 UNIT-  
61,500 UNIT CAPSULE,DELAYED  
RELEASE.....11

PANCREAZE 16,800 UNIT-56,800 UNIT-  
98,400 UNIT CAPSULE,DELAYED  
RELEASE.....11

PANCREAZE 2,600 UNIT-6,200 UNIT-  
10,850 UNIT CAPSULE,DELAYED  
RELEASE.....11

PANCREAZE 21,000 UNIT-54,700 UNIT-  
83,900 UNIT CAPSULE,DELAYED  
RELEASE.....11

PANCREAZE 4,200 UNIT-14,200 UNIT-  
24,600 UNIT CAPSULE,DELAYED  
RELEASE.....11

### R

RELISTOR 12 MG/0.6 ML  
SUBCUTANEOUS SOLUTION .....12

RELISTOR 12 MG/0.6 ML  
SUBCUTANEOUS SYRINGE.....12

RELISTOR 8 MG/0.4 ML  
SUBCUTANEOUS SYRINGE.....12

RESTASIS 0.05 % EYE DROPS IN A  
DROPPERETTE .....8

rivastigmine 13.3 mg/24 hour transdermal  
patch .....13

rivastigmine 4.6 mg/24 hour transdermal  
patch .....13

rivastigmine 9.5 mg/24 hour transdermal  
patch .....13

### S

SIMBRINZA 1 %-0.2 % EYE  
DROPS,SUSPENSION .....2

### T

TRINTELLIX 10 MG TABLET .....3

TRINTELLIX 20 MG TABLET .....3

TRINTELLIX 5 MG TABLET .....3

### V

VIIBRYD 10 MG (7)-20 MG (23)  
TABLETS IN A DOSE PACK .....3

VIIBRYD 10 MG TABLET.....3

VIIBRYD 20 MG TABLET.....3

VIIBRYD 40 MG TABLET.....3